Targeting heterogeneity in atypical epidermal growth factor receptor-mutated non-small cell lung cancer: insights from CHRYSALIS-2
Yosuke Dotsu, Hiroshi Mukae · 2026
Read Targeting heterogeneity in atypical epidermal growth factor receptor-mutated non-small cell lung cancer: insights from CHRYSALIS-2 by Yosuke Dotsu, Hiroshi Mukae (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263881.txt.
Description
Yosuke Dotsu and Hiroshi Mukae commented in 2026 on a trial cohort tackling the neglected corner of EGFR-mutated lung cancer: the atypical mutations. Drugs built for the two classic changes transformed care, yet ten to fifteen percent of mutated tumors carry rarer variants that answer unevenly. Their editorial reads the CHRYSALIS-2 experience for lessons.
The cohort tested a bispecific antibody, amivantamab, paired with the blocker lazertinib in patients whose mutations fall outside the classic pair. Atypical changes vary widely in structure, so one drug rarely fits all of them. The commentators place the results against the strong benchmarks set in classic disease. They weigh which atypical subtypes gained most and where resistance still wins. Their verdict favors antibody-based combinations as the practical route forward for this heterogeneous group.
Catalog record
| CREATOR | Yosuke Dotsu, Hiroshi Mukae |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |